ATE145336T1 - Stabilisierter varizella-lebendimpfstoff - Google Patents

Stabilisierter varizella-lebendimpfstoff

Info

Publication number
ATE145336T1
ATE145336T1 AT92113567T AT92113567T ATE145336T1 AT E145336 T1 ATE145336 T1 AT E145336T1 AT 92113567 T AT92113567 T AT 92113567T AT 92113567 T AT92113567 T AT 92113567T AT E145336 T1 ATE145336 T1 AT E145336T1
Authority
AT
Austria
Prior art keywords
ions
stabilizer
vaccine
gelatin
live
Prior art date
Application number
AT92113567T
Other languages
English (en)
Inventor
Kuniaki Koyama
Juichiro Osame
Original Assignee
Univ Osaka Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Osaka Res Found filed Critical Univ Osaka Res Found
Application granted granted Critical
Publication of ATE145336T1 publication Critical patent/ATE145336T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0015—Combination vaccines based on measles-mumps-rubella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AT92113567T 1992-05-05 1992-08-08 Stabilisierter varizella-lebendimpfstoff ATE145336T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP15723692 1992-05-05
JP14847692 1992-05-15

Publications (1)

Publication Number Publication Date
ATE145336T1 true ATE145336T1 (de) 1996-12-15

Family

ID=26478665

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92113567T ATE145336T1 (de) 1992-05-05 1992-08-08 Stabilisierter varizella-lebendimpfstoff

Country Status (8)

Country Link
US (2) US5948411A (de)
EP (1) EP0568726B1 (de)
KR (1) KR0149677B1 (de)
AT (1) ATE145336T1 (de)
AU (1) AU2088992A (de)
CA (1) CA2075521C (de)
DE (1) DE69215355T2 (de)
TW (1) TW205570B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0679088B1 (de) 1992-09-29 2002-07-10 Inhale Therapeutic Systems Pulmonale abgabe von aktiven fragmenten des parathormons
ATE416755T1 (de) 1994-03-07 2008-12-15 Nektar Therapeutics Verfahren und zusammensetzung für die pulmonale darreichung von insulin
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
GB2293100A (en) * 1994-09-15 1996-03-20 Medeva Europ Ltd Pharmaceutical compositions with deuterium oxide
US6290967B1 (en) * 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
US6051238A (en) * 1996-12-20 2000-04-18 Merck & Co., Inc. Stabilizers for lyophilized mumps vaccines
CA2274755A1 (en) * 1996-12-20 1998-07-02 Su-Pi Sheu Stabilizers for lyophilized vaccines
US6210683B1 (en) * 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
CN1053590C (zh) * 1998-10-19 2000-06-21 卫生部长春生物制品研究所 冻干甲型肝炎减毒活疫苗及其保护剂
CN1062770C (zh) * 1998-11-12 2001-03-07 卫生部长春生物制品研究所 甲肝-麻疹二联疫苗及其生产方法
RU2002112751A (ru) 1999-11-12 2004-02-27 Файброджен, Инк. (Us) Рекомбинантные желатины
US7456009B2 (en) * 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
JP5118798B2 (ja) * 2000-03-07 2013-01-16 メルク・シャープ・エンド・ドーム・コーポレイション アデノウイルス製剤
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
KR100385711B1 (ko) * 2000-07-05 2003-05-27 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
FR2814957B1 (fr) * 2000-10-06 2002-12-20 Aventis Pasteur Composition vaccinale et procede de stabilisation
US20040033239A1 (en) * 2001-03-06 2004-02-19 Evans Robert K Adenovirus formulations
PT1458360E (pt) 2001-12-19 2011-07-13 Novartis Ag Derivados de indole como agonistas do recetor s1p1
US7465456B2 (en) * 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
DK1499348T3 (en) 2002-04-26 2015-01-05 Medimmune Llc PROCEDURE FOR PREPARING INFECTIOUS INFLUENZA B-VIRA IN CELL CULTURE
US20060110406A1 (en) * 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
EP2481819A1 (de) 2003-02-25 2012-08-01 MedImmune Vaccines, Inc. Querstromfiltration in der Herstellung von stabilisierten Influenza-Impfstoff-Zusammensetzungen
CA2551489C (en) 2003-12-23 2013-09-03 Gregory Duke Multi plasmid system for the production of influenza virus
EP1708747A2 (de) * 2004-01-15 2006-10-11 Intervet International BV Stabilisatoren nichttierischen ursprungs und herstellungsverfahren dafür
CA2571261C (en) * 2004-06-29 2018-08-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Safer attenuated virus vaccines with missing or diminished latency of infection
EP2769735B1 (de) * 2004-10-06 2017-04-19 MedImmune, LLC Kühlschranktemperaturstabile Grippeimpfstoff-zusammensetzungen
US20060141483A1 (en) * 2004-12-23 2006-06-29 Calton Gary J Stabilization of viral compositions
EP1954308B1 (de) * 2005-09-16 2011-09-07 Merial Ltd. Stabilisatoren für gefriergetrocknete impfstoffe
WO2008079539A2 (en) 2006-11-09 2008-07-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant herpesvirus with diminished latency and methods of using same
EP2674486A1 (de) * 2007-06-18 2013-12-18 MedImmune, LLC Influenza-B-Viren mit Veränderungen im Hämagglutininpolypeptid
AU2008339980A1 (en) * 2007-12-21 2009-07-02 Glaxosmithkline Biologicals S.A. Vaccines for malaria
WO2009080719A1 (en) * 2007-12-21 2009-07-02 Glaxosmithkline Biologicals S.A. Vaccine
EP2646051A4 (de) 2010-12-02 2014-05-28 Oncolytics Biotech Inc Flüssige virale formulierungen
MX349294B (es) 2010-12-02 2017-07-21 Oncolytics Biotech Inc Formulaciones virales liofilizadas.
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
US9480739B2 (en) * 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
CN105582534A (zh) * 2014-10-22 2016-05-18 上海生物制品研究所有限责任公司 一种无明胶水痘疫苗冻干制剂及其制备方法
US10815456B2 (en) 2016-10-04 2020-10-27 Transwell Biotech Co., Ltd. Composition, kit and method for cryopreserving cells
CA3174826A1 (en) * 2021-01-19 2022-07-28 Katsuro HAGIWARA Virus stabilizer, gelatin hydrolysate for virus stabilizer, and virus-containing composition
CN115227811B (zh) * 2022-08-26 2023-07-28 上海荣盛生物药业股份有限公司 一种水痘-带状疱疹病毒活疫苗原液的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1403608A (fr) * 1961-04-04 1965-06-25 Behringwerke Ag Procédé de stabilisation de cultures d'agents pathogènes
US3915794A (en) * 1973-02-09 1975-10-28 Rit Rech Ind Therapeut Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them
US4000256A (en) * 1975-04-30 1976-12-28 Merck & Co., Inc. Varicella vaccine and process for its preparation
PT71926B (en) * 1979-10-29 1982-03-31 Merck & Co Inc Process for preparing a liquid vaccine comprising a stabilizer
US4338335A (en) * 1980-02-05 1982-07-06 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
US4337242A (en) * 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
US4452734A (en) * 1980-02-11 1984-06-05 Merck & Co., Inc. Herpes subunit vaccine
JPS5716823A (en) * 1980-07-03 1982-01-28 Green Cross Corp:The Live mumps vaccine pharmaceutical and stabilizing method
US4464474A (en) * 1980-07-09 1984-08-07 Connaught Laboratories Limited Non-A, non-B hepatitis assay and vaccine
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
JPS6314729A (ja) * 1986-06-30 1988-01-21 スミスクライン・バイオロジカルス・ソシエテ・アノニム 生ワクチン用改良安定剤、その製造法およびそれを含有するワクチン
CA1337859C (en) * 1987-04-24 1996-01-02 Masashi Chazono Method for culturing bordetella pertussis, a pertussis toxoid and a pertussis vaccine
JPS63307827A (ja) * 1987-06-08 1988-12-15 Kitasato Inst:The 安定化された生ウイルスワクチンおよびその製造法

Also Published As

Publication number Publication date
TW205570B (en) 1993-05-11
DE69215355D1 (de) 1997-01-02
EP0568726A2 (de) 1993-11-10
EP0568726B1 (de) 1996-11-20
US5948411A (en) 1999-09-07
KR930023039A (ko) 1993-12-18
EP0568726A3 (de) 1994-08-31
CA2075521A1 (en) 1993-11-06
DE69215355T2 (de) 1997-04-24
CA2075521C (en) 1995-11-28
AU2088992A (en) 1993-11-11
US6039958A (en) 2000-03-21
KR0149677B1 (ko) 1998-10-15

Similar Documents

Publication Publication Date Title
ATE145336T1 (de) Stabilisierter varizella-lebendimpfstoff
TW284692B (de)
DE3483869D1 (de) Zusammensetzungen zur bekaempfung von toxaemia.
ATE245033T1 (de) Verwendung von metallionen chelatoren zur stabilisierung von interferon-enthaltenden pharmazeutischen zubereitungen
NO863253D0 (no) Fremgangsmaate for fremstilling av et vandig vaeskeformig preparat.
IL98479A0 (en) Hexahydroazepine derivatives,their preparation and pharmaceutical compositions containing them
IL79699A (en) Antiviral compositions containing 2',3'-dideoxycytidine or its mono-or triphosphate
CS9100490A2 (en) Ethylen-1-penten copolymer, method of its preparation and its composition
ATE156473T1 (de) Verfahren zur verringerung von verunreinigungen in wässrigen monomerlösungen
EA199900888A1 (ru) Противоревматические средства
DK488586D0 (da) Stabiliseret interferon
DK484988D0 (da) Thionophosphonsyreestere, deres fremstilling og anvendelse til bekaempelse af skadelige organismer
DE3561948D1 (en) Oximinophosphoric acid derivatives, process for their preparation and their use as pesticides
DK0387655T3 (da) Stabilisering af polyprenylforbindelse
NO954664D0 (no) Fremstilling av symmetriske eller usymmetriske substituerte N-cyanoditio-iminokarbonater
ATE61372T1 (de) Thionophosphonsaeureester.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties